Business
Potential of Preclinical Program in Mental Fatigue
TheraCryf plc is highlighting the potential of its second preclinical program, DAT, which targets mental and cognitive fatigue, a condition linked to low dopamine levels. The chronic fatigue treatment market was valued at US$1.2 billion in 2024 and is projected to reach US$2.3 billion by 2033. TheraCryf's DAT asset aims to gradually increase brain dopamine without the abuse potential of current stimulants, showing positive preclinical proof of concept in models of drug-induced fatigue, MS fatigue, and narcolepsy, a market valued at US$3.48 billion in 2024. Disclaimer*
About this update from Theracryf Plc
[{"type":"text","content":"\n\n\n \nTheraCryf plc\n(\"TheraCryf\", the \"Company\" or the \"Group\")\n \nTheraCryf Highlights Potential of Second Preclinical Programme\nTargeting Mental and Cognitive Fatigue\n· Chronic fatigue treatment market worth US$1.2 billion in 2024, rising to c.US$2.3bn by 20331\n· Recent Nature article indicates extent of mental fatigue problem2\n· Low levels of dopamine in the brain are linked to mental and cognitive fatigue\n· TheraCryf's dopamine modulator (DAT) offers a potential treatment for chronic fatigue\n· Asset at late preclinical stage with published data demonstrating effectiveness at alleviating fatigue in established models \nAlderley Park, 18 December 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, notes a recent Nature article2 which discusses the extent of the issue of mental fatigue and highlights the commercial opportunity provided by its second pre-clinical programme, DAT, which has the potential to treat fatigue.\nCentral nervous system fatigue is associated with diseases such as multiple sclerosis (MS), myalgic encephalomyelitis (ME), long COVID and chemotherapy treatment. More than 80% of patients with multiple sclerosis suffer from fatigue and report it as the most common and debilitating symptom3. This overwhelming cognitive exhaustion, which is not simply being 'tired', severely impacts daily life. Currently there are no approved treatments for fatigue in these patients.\nThe potential market opportunity for treating chronic fatigue was estimated at US$1.2 billion in 2024 with the market expected to reach US$2.3 billion by 20331.\nGrowing scientific interest in the origins of mental fatigue is underscored by the recent Nature article2 by Lynne Peeples which highlights the research being undertaken to discover the roots of mental fatigue which could point to treatments for these debilitating disorders. Dopamine plays a major role in alertness and motivation with low levels being linked to fatigue states4.\nCurrent treatments include stimulants, such as amphetamines, which produce a rapid rise in dopamine, however, they are associated with significant side effects and a high potential for abuse because of the 'rush'-like feelings they prod...